JWH-192

Chemical Compound
Identifiers
CAS Number
PubChem CID
ChemSpider ID
UNII
ChEBI
ChEMBL
Properties
Chemical Formula
Molar Mass
Appearance
Density
Melting Point
Boiling Point
Hazards
GHS Pictograms	[[File:|50px]]
GHS Signal Word
GHS Hazard Statements
NFPA 704	[[File:|50px]]
References

JWH-192 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of the JWH series of synthetic cannabinoids, which were developed by Dr. John W. Huffman in the 1990s for research purposes. JWH-192 is known for its high affinity for the CB1 receptor, which is primarily found in the brain, and the CB2 receptor, which is primarily found in the immune system.

Chemical Structure and Properties

JWH-192 is chemically classified as a naphthoylindole, a class of compounds that are structurally related to the naturally occurring cannabinoids found in the Cannabis plant. The IUPAC name for JWH-192 is (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone. Its molecular formula is C₂₃H₃₁NO, and it has a molecular weight of 337.50 g/mol.

The structure of JWH-192 includes a pentyl chain attached to the indole core, which is a common feature among synthetic cannabinoids that contributes to their activity at cannabinoid receptors. The presence of the tetramethylcyclopropyl group is a distinctive feature that influences the compound's binding affinity and selectivity.

Pharmacology

JWH-192 acts as a full agonist at both the CB1 and CB2 receptors, with a higher affinity for the CB1 receptor. This receptor is responsible for the psychoactive effects of cannabinoids, as it is predominantly located in the central nervous system. Activation of the CB1 receptor by JWH-192 can lead to effects such as altered perception, mood changes, and impaired cognitive function.

The CB2 receptor, on the other hand, is primarily associated with the immune system and its activation by JWH-192 may influence immune responses and inflammation.

Legal Status

Due to its potential for abuse and lack of medical use, JWH-192, like many other synthetic cannabinoids, has been classified as a controlled substance in many countries. It is often included in legislation that targets synthetic cannabinoids as a class, rather than individual compounds.

Research and Applications

JWH-192, along with other synthetic cannabinoids, has been used in scientific research to study the endocannabinoid system and to develop potential therapeutic agents. However, its use is limited due to its legal status and potential for abuse.

Health Effects and Risks

The use of JWH-192, particularly in recreational settings, poses significant health risks. These can include acute intoxication, cardiovascular effects, and potential for addiction. The lack of regulation and quality control in the production of synthetic cannabinoids further increases the risk of adverse effects.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• JWH series
• John W. Huffman
• Endocannabinoid system